4//SEC Filing
Curnutte John T 4
Accession 0001209191-19-031875
CIK 0001269021other
Filed
May 20, 8:00 PM ET
Accepted
May 21, 8:20 PM ET
Size
13.2 KB
Accession
0001209191-19-031875
Insider Transaction Report
Form 4
Curnutte John T
Executive Vice President
Transactions
- Award
Common Stock
2019-05-17+4,688→ 103,227 total - Exercise/Conversion
Performance Stock Unit
2019-05-17−4,688→ 0 totalExp: 2027-01-30→ Common Stock (4,688 underlying) - Award
Common Stock
2019-05-17+1,750→ 104,977 total - Tax Payment
Common Stock
2019-05-20$28.69/sh−2,418$69,372→ 102,559 total - Tax Payment
Common Stock
2019-05-20$28.69/sh−903$25,907→ 101,656 total
Footnotes (3)
- [F1]Each Performance Stock Unit (PSU) granted January 30, 2017 represented a contingent right to receive one (1) share of Issuer's Common Stock. 4,688 would have vested upon the one year anniversary of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018 but vesting was accelerated under the Reporting Person's Enhanced Severance Agreement upon Reporting Person's retirement and approval of the accelateration.
- [F2]Each Performance Stock Unit (PSU) granted March 29, 2018 represented a contingent right to receive one (1) share of Issuer's Common Stock. 1,750 would have vested upon the one year anniversary of the Compensation Committee's certification of the FDA's December 31, 2018 approval of Andexxa Gen 2 in the United States but vesting was accelerated under the Reporting Person's Enhanced Severance Agreement upon Reporting Person's retirement and approval of the acceleration.
- [F3]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
Documents
Issuer
PORTOLA PHARMACEUTICALS INC
CIK 0001269021
Entity typeother
Related Parties
1- filerCIK 0001574589
Filing Metadata
- Form type
- 4
- Filed
- May 20, 8:00 PM ET
- Accepted
- May 21, 8:20 PM ET
- Size
- 13.2 KB